To read a factual account of the true history of Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More, please visit Pompe Disease—The Real Story.

The AMDA issued a press release regarding the film, Extraordinary Measures. The press release can be found here. In addition, the AMDA created a one-page fact sheet regarding Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More to help raise awareness of the condition. That fact sheet can be found...

This information was complied from the information provided on clinicaltrials.gov. To read, please download file by clicking here.

Genzyme would like to provide an update to the US Pompe community about the status of the Alglucosidase AlfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More Temporary Access Program (ATAP) and the application for Lumizyme™ (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More) approval in the United States. In a press release dated December 3,...

Guidelines from Erasmus Medical Centre, Rotterdam, the Netherlands As a guideline we recommend that all patients with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More are vaccinated against influenza. This applies both to the seasonal influenza as well as for the 2009 flu pandemic (influenza virus...

Genzyme Manufacturing Update Genzyme invites all patients to participate in a forum to discuss recent FDA reports and media attention related to manufacturing operations in Allston, Massachusetts. Date: Monday, November 23, 2009 Time: 6:00 PM – 7:00 PM (EST) US Toll...

Genzyme would like to provide an update to the US Pompe community about the status of the application for Lumizyme™ (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More) produced at the 2000 L scale in the United States. To read full Program Update, please click here.

CRANBURY, N.J., Sept 30, 2009 - - Amicus Therapeutics today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More. The primary objective of this study is to...

In their second quarter earning statement, Genzyme provided an update on the situation at the Allston manufacturing plant, and the US LumizymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More application. To read full statement, please click here.

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items in the FDA’s complete response letter for LumizymeTM (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More), produced at the 2,000 L bioreactor scale. The submission...